MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
home > drug information > Nasacort AQ

Nasacort AQ (triamcinolone acetonide) Nasal Spray


Company: Rhone Poulenc Rorer
Approval Status: Approved May 1996
Treatment for: allergic rhinitis
Areas: Pulmonary/Respiratory Diseases
Possible similar drugs: Nasacort AQ

| General Information | Clinical Results | Side Effects | Additional Information |


General Information

Other Useful Resources

Nasacort AQ Nasal Spray has been approved for the treatment of seasonal and perennial allergic rhinitis symptoms indicated for adults and children over the age of 12.

Contained in an aqueous microcrystalline suspension that does not use chloroflurocarbon (CFC) propellants, Nasacort AQ represents a new formulation of the active ingredient, triamcinolone acetonide. RPR will also continue to market its once-daily aerosol formulation of triamcinolone acetonide.

Each metered pump spray bottle of Nasacort AQ provides at least 120 actuations. It is recommended that once-daily dosing begin at 220 micrograms (two sprays in each nostril) for adults and children 12 years and older.



< back to top

Clinical Results

The safety and efficacy of Nasacort AQ has been demonstrated in ten placebo-controlled, double-blind studies involving more than 1,200 subjects ages 12 years and older with seasonal or perennial allergic rhinitis. These studies showed that compared to placebo, once-daily Nasacort AQ provides statistically significant relief of nasal symptoms including sneezing, stuffiness, discharge, and itching.



< back to top

Side Effects

Nasacort AQ is generally well tolerated. The most commonly reported side effects observed in clinical trials included sore throat, nosebleed, and cough.



< back to top

Additional Information

An estimated 40 million Americans suffer from seasonal and perennial allergic rhinitis, which produce symptoms including nasal itch, congestion, runny nose, sneezing, and watery eyes.

Seasonal allergic rhinitis--commonly known as hay fever--is caused by allergens present at specific times of the year, such as tree pollens in the spring. Perennial allergic rhinitis is caused by allergens in the environment all year, such as dust mites, mold, mildew, or pet dander.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.